The oral selective oestrogen receptor degrader (SERD) AZD9496 is comparable to fulvestrant in antagonising ER and circumventing endocrine resistance

por Nardone, Agostina, Weir, Hazel, Delpuech, Oona, Brown, Henry, De Angelis, Carmine, Cataldo, Maria Letizia, Fu, Xiaoyong, Shea, Martin J., Mitchell, Tamika, Veeraraghavan, Jamunarani, Nagi, Chandandeep, Pilling, Mark, Rimawi, Mothaffar F., Trivedi, Meghana, Hilsenbeck, Susan G., Chamness, Gary C., Jeselsohn, Rinath, Osborne, C. Kent, Schiff, Rachel
Publicado no Br J Cancer (2018)

Evaluation of the predictive role of tumor immune infiltrate in HER2-positive breast cancer patients treated with neoadjuvant anti-HER2 therapy without chemotherapy

por De Angelis, Carmine, Nagi, Chandandeep, Hoyt, Cliff C., Liu, Linying, Roman, Kristin, Wang, Chichung, Zheng, Yi, Veeraraghavan, Jamunarani, Sethunath, Vidyalakshmi, Nuciforo, Paolo, Wang, Tao, Tsimelzon, Anna, Mao, Sufeng, Hilsenbeck, Susan G., Trivedi, Meghana V., Cataldo, Maria Letizia, Pavlick, Anne C., Wolff, Antonio C., Weigelt, Britta, Reis-Filho, Jorge S., Prat, Aleix, Gutierrez, Carolina, Osborne, C. Kent, Rimawi, Mothaffar F., Schiff, Rachel
Publicado no Clin Cancer Res (2019)